Harrow, Inc. (HROW) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Harrow, Inc. is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic products in the U.S. market. The company operates two primary segments: Branded (FDA-approved ophthalmic products) and ImprimisRx (ophthalmology-focused pharmaceutical compounding). This report covers the quarterly period ended March 31, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenues | $47.83 million | $34.59 million |
| Gross Profit | $32.31 million | $24.03 million |
| Gross Margin | 67.5% | 69.5% |
| Net Loss | $(17.78) million | $(13.57) million |
| Net Loss Per Share (Basic/Diluted) | $(0.50) | $(0.38) |
| Cash and Cash Equivalents | $66.73 million | $68.54 million |
| Operating Cash Flow | $19.67 million | $(4.63) million |
| Total Debt (Principal) | $226.51 million | $226.51 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $13.24 million (38.3%) year-over-year, driven primarily by the Branded segment.
- Product Performance:
- VEVYE: Revenue surged to $21.52 million from $2.60 million in Q1 2024.
- IHEEZO: Revenue grew to $5.22 million from $2.32 million.
- Other Branded: Declined to $0.96 million from $8.87 million due to the phase-out of certain legacy products.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased by $11.70 million to $40.51 million, attributed to seasonal audit costs, special projects, and hiring to support growth. R&D expenses rose by $0.88 million to $3.03 million.
- Cash Flow: Operating cash flow turned positive at $19.67 million, a significant improvement from a $4.63 million outflow in the prior year, largely due to a $39.2 million reduction in accounts receivable.
- Debt Reclassification: The Oaktree Loan ($107.5 million principal) was reclassified from long-term to current liabilities as it matures in January 2026.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: The company faces significant debt maturities in 2026: the Oaktree Loan ($107.5 million) in January and 8.625% Senior Notes ($75.0 million) in April. Management states there is "substantial doubt" about the ability to continue as a going concern if these obligations are not refinanced. Management is in discussions with lenders and believes refinancing is probable but not assured.
- Strategic Initiatives:
- VEVYE Access for All: Launched a patient access program to reduce out-of-pocket costs to $59 or below.
- Project Beagle: A 360-degree review to transition ImprimisRx patients from compounded formulations (e.g., Klarity-C) to FDA-approved Harrow products (e.g., VEVYE). Klarity-C compounding is expected to cease by June 30, 2025.
- Legal Proceedings: In November 2024, a jury awarded Harrow $34.9 million in damages against Ocular Science, Inc. (OSRX) for trademark infringement and unfair competition. Due to uncertainty regarding collection, this amount has not been recognized in the financial statements.
- Subsequent Events: In April 2025, the company settled 1.57 million Performance Stock Units (PSUs) after achieving total stock price targets, issuing 1.02 million shares and withholding 0.55 million shares for taxes.
Investor Verification Checklist
- Refinancing Status: Verify the progress of negotiations with Oaktree and other lenders regarding the $182.5 million in debt maturing in 2026.
- Collection of Legal Award: Monitor the status of the $34.9 million verdict against OSRX and the likelihood of collection.
- Product Transition Impact: Assess the financial impact of "Project Beagle" on ImprimisRx revenue as compounded products are discontinued in favor of branded alternatives.
- Covenant Compliance: Confirm continued compliance with financial covenants (minimum liquidity and net revenues) under the Oaktree Loan.
- Accounts Receivable Quality: Review the concentration risk, as two customers accounted for 90% of total consolidated accounts receivable as of March 31, 2025.